Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
EU approves Dupixent for treating eosinophilic esophagitis in young children
EMA approves Sanofi and Regeneron's Dupixent for treating eosinophilic esophagitis in children aged 1-11 years, marking the first EU approval for this age group. Dupixent, a monoclonal antibody targeting IL4 and IL13 pathways, showed efficacy in a phase 3 trial, with 68% of children achieving histological disease remission.
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies
DelveInsight's 'Severe Asthma Pipeline Insight 2024' highlights 40+ companies developing 50+ therapies, including promising candidates like KN-002, BAT2606, CM326, and others. Key companies include Kinaset Therapeutics, GlaxoSmithKline, Sanofi, and AstraZeneca. Recent milestones include positive phase III results for GSK's depemokimab and phase IIb data for Sanofi's rilzabrutinib. The report covers global pipeline, therapeutic assessments, and key insights on severe asthma treatment.
Sanofi, Regeneron Dupixent approved in EU for young children with eosinophilic esophagitis
Dupixent is now approved in the EU for treating eosinophilic esophagitis (EoE) in children aged 1-11, making it the first and only medicine indicated for this age group. The approval is based on the EoE KIDS phase 3 study, showing Dupixent's efficacy and safety in children similar to older EoE patients. Dupixent, an injection inhibiting IL4 and IL13 pathways, aims to improve the quality of life for young EoE patients.
EMA approves Dupixent for young EoE patients
EMA approved Sanofi/Regeneron’s Dupixent for EoE in children aged 1-11, based on EoE KIDS trial results. Dupixent is the first approved treatment for young EoE patients in EU, Canada, and US.
EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year
The European Medicines Agency approves Dupixent for eosinophilic esophagitis in children aged 1-11 years, making it the first treatment for this age group. The approval is based on the EoE KIDS phase 3 study showing Dupixent's efficacy and safety in children, with 68% achieving histological disease remission compared to 3% with placebo. Dupixent is administered subcutaneously and inhibits the IL4 and IL13 pathways, addressing type-2 inflammation.
Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of drug approvals
Top 20 biopharmaceutical companies saw a 2% market cap increase in Q3 2024, driven by FDA approvals and strategic alliances. Bristol Myers Squibb led with a 24.6% growth, fueled by Cobenfy's approval and a $3.5bn deal with Prime Medicine. Gilead Sciences and Sanofi also grew significantly due to new drug approvals. Despite some declines, industry recovery is expected, supported by Federal Reserve interest rate cuts.
A diabetes drug, twice rejected, stumbles again — but its developer persists
Lexicon Pharmaceuticals faces FDA rejections for sotagliflozin, its type 1 diabetes and chronic kidney disease drug, with an advisory committee voting against its approval. Despite setbacks, Lexicon continues development and anticipates an FDA decision by December 20.
Dupixent approved in the EU as the first and only medicine for young children with ...
The European Medicines Agency approved Dupixent for treating eosinophilic esophagitis in children aged one to 11 years, based on phase 3 data showing significant histological disease remission at 16 weeks, sustained up to one year. Dupixent is the first medicine in the EU indicated for these young patients, addressing a critical need where growth is crucial.
T-Cell Lymphoma Pipeline Insight Analysis Report 2024
The 'T-Cell Lymphoma Pipeline Insight Analysis Report' highlights key players like Legend Biotech, Eisai, Takeda, and Rhizen Pharmaceuticals developing treatments such as Lenalidomide, BMS-986369, and Isatuximab SAR650984. Regulatory support, including fast-track designations, drives innovation, aiming for better patient outcomes. The pipeline focuses on immune-modulating drugs, monoclonal antibodies, and targeted therapies, with Phase II trials dominating.
© Copyright 2025. All Rights Reserved by MedPath